$NUS News

Nu Skin Enterprises Stockholders Approve Amended And Restated 2024 Omnibus Incentive Plan; Amended Plan Increases Share Authorization By 2.85M Shares; Plan Termination Date Extended To May 28, 2036

Nu Skin Enterprises, Inc. 2026 Q1 - Results - Earnings Call Presentation

Nu Skin Enterprises, Inc. (NUS) Q1 2026 Earnings Call Transcript

Nu Skin Enterprises (NYSE:NUS) Reports Q1 2026 Earnings Miss Amid Ongoing Revenue Decline

Nu Skin Enterprises Lowers FY2026 GAAP EPS Guidance from $0.80-$1.20 to $0.70-$1.10 vs $1.00 Est; Affirms FY2026 Sales Guidance of $1.350B-$1.500B vs $1.427B Est

Nu Skin Enterprises Sees Q2 GAAP EPS $0.15-$0.25 vs $0.23 Est; Sees Sales $330.000M-$360.000M vs $361.000M Est

Nu Skin Enterprises Q1 Adj. EPS $0.14 Misses $0.15 Estimate, Sales $320.600M Miss $329.700M Estimate

Nu Skin Enterprises to Announce First Quarter 2026 Financial Results

Nu Skin Launches Prysm iO™: A Revolutionary AI-Powered Platform for Personalized Nutritional Wellness

Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer

Nu Skin Enterprises Appoints Chelsea Lantz Interim CFO, Effective Immediately, Succeeding James Thomas

Nu Skin Appoints Chayce Clark as COO

Nu Skin Enterprises Appoints Chayce Clark COO, Effective Immediately

Nu Skin Still Has Long-Term Turnaround Potential

Nu Skin Enterprises, Inc. 2025 Q4 - Results - Earnings Call Presentation

Estimating The Fair Value Of Nu Skin Enterprises, Inc. (NYSE:NUS)

Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2025 Q4

Nu Skin Enterprises, Inc. Q4 2025 Earnings Call Summary

Nu Skin Enterprises shares are trading lower after the company reported worse-than-expected Q4 financial results and issued Q1 and FY26 guidance below estimates.

Nu Skin Enterprises shares are trading lower after the company reported worse-than-expected Q4 financial results and issued Q1 and FY26 guidance below estimates.